Stonegate Investment Group LLC Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Stonegate Investment Group LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 0.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 537,343 shares of the company's stock after acquiring an additional 2,448 shares during the quarter. Johnson & Johnson accounts for 2.4% of Stonegate Investment Group LLC's holdings, making the stock its 13th biggest position. Stonegate Investment Group LLC's holdings in Johnson & Johnson were worth $89,113,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Lantz Financial LLC lifted its position in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after purchasing an additional 377 shares during the period. Sulzberger Capital Advisors Inc. acquired a new position in Johnson & Johnson during the fourth quarter valued at $453,000. Horan Securities Inc. lifted its position in Johnson & Johnson by 1.3% during the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock valued at $1,038,000 after purchasing an additional 90 shares during the period. State of Wyoming lifted its position in Johnson & Johnson by 205,580.0% during the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after purchasing an additional 10,279 shares during the period. Finally, Range Financial Group LLC lifted its position in Johnson & Johnson by 18.9% during the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after purchasing an additional 2,529 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on JNJ. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 5th. Finally, Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Eleven equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Stock Down 0.6%

JNJ stock opened at $149.81 on Friday. The stock has a market capitalization of $360.44 billion, a P/E ratio of 16.66, a P/E/G ratio of 2.27 and a beta of 0.42. The firm has a 50-day simple moving average of $154.07 and a 200-day simple moving average of $153.65. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.47%. The ex-dividend date of this dividend was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.